On February 4, 2025, Rallis India informed the exchanges that SBI Mutual Fund has increased its shareholding in their company under its various schemes. This marks a rise of 2% from its previous disclosure made as per Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. As of December 31, 2024, SBI Mutual Fund’s holding stood at 7.0577% of Rallis India’s paid-up share capital.

Recently, SBI Mutual Fund purchased 1,492,759 additional shares, representing 0.7676% of Rallis India’s paid-up share capital. Following this acquisition, the total shareholding of SBI Mutual Fund across its schemes has reached 17,826,452 shares, which is equivalent to 9.1667% of Rallis India’s paid-up share capital as of January 31, 2025.

Rallis India Share Price Performance

On February 5, 2025, Rallis India share price opened at ₹238.01, up from its previous close of ₹236.65. At 10:16 AM, the share price of Rallis India was trading at ₹246.24, up by 4.05% on the NSE.

About Rallis India Ltd

Rallis India, a Tata Group company with a legacy spanning over 150 years, specialises in manufacturing agrochemicals. The company operates across the entire agriculture input value chain, offering products ranging from seeds to organic plant growth nutrients. Additionally, Rallis engages in contract manufacturing for global corporations.

Plan your SBI SIP investments better! Use our easy-to-use SBI SIP Calculator and estimate future returns with just a few clicks. Your financial growth starts here.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

MAS Financial Services Limited’s Board of Directors has declared and approved an interim dividend of ₹1 (10%) per equity share of face value ₹10 each.

On February 5, 2025, MAS Financial Services share price opened at ₹250.65, down from its previous close of ₹252.25. At 9:39 AM, the share price of MAS Financial Services was trading at ₹254.40, up by 1.25% on the NSE. Notably, the stock price touched its 52-week high at ₹229.40 on January 27, 2025.

MAS Financial Services Dividend Record Date

On January 29, 2025, the company’s Board of Directors declared an interim dividend of ₹1 per equity share, representing 10% of the face value of ₹10. The record date for the interim dividend is set as Wednesday, February 5, 2025.

Q3 FY 2025 Financial Highlights

MAS Financial Services Limited, on a consolidated basis, reported Assets Under Management (AUM) of ₹12,378.80 crore and Profit After Tax (PAT) of ₹80.21 crore for the quarter ended December 31, 2024. This marks a growth of 21.17% in AUM and 24.83% in PAT compared to ₹10,215.05 crore and ₹64.27 crore, respectively, for the same period in 2023. The consolidated disbursement during the quarter was ₹3,227.72 crore.

About MAS Financial Services Ltd

MAS Financial Services Limited is a non-deposit-taking NBFC registered with the RBI. It is involved in providing retail financing products for MSMEs, home loans, two-wheeler loans, used car loans and commercial vehicle loans.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Sun Pharmaceutical Industries Limited’s Board of Directors has declared and approved an interim dividend of ₹10.50 per equity share.

On February 5, 2025, Sun Pharma share price opened at ₹1,773.80, up from its previous close of ₹1,765.25. However, at 9:36 AM, the share price of Sun Pharmaceutical Industries was trading at ₹1,753.50, down by 0.67% on the NSE.

Sun Pharmaceutical Industries Dividend Record Date

The company has declared an interim dividend of ₹10.50 (Rupees Ten and Paise Fifty) per equity share of ₹1 (Rupee One) each for the financial year 2024-25. As announced on January 16, 2025, the record date for determining eligibility for the interim dividend is February 6, 2025. The payment of the interim dividend will be made on or before February 20, 2025.

9M FY 2025 Financial Highlights

Gross sales for the period reached ₹3,92,257 million, reflecting a growth of 9.1%. India formulation sales stood at ₹1,27,100 million, recording an impressive 13.7% increase. Meanwhile, US formulation sales amounted to $1,457 million, up by 5.7%, showcasing steady growth in international markets.

EBITDA, including other operating revenues, surged by 15.7% to ₹115,556 million, achieving an EBITDA margin of 29.2%. Net profit for the first nine months of FY25 was ₹87,792 million. On a like-for-like basis, the adjusted net profit stood at ₹90,953 million, marking a 24.3% year-on-year growth.

About Sun Pharmaceutical Industries Ltd

Sun Pharma is a global leader in speciality generics, offering a wide range of products in Specialty, Generics, and Consumer Healthcare. It is India’s largest pharmaceutical company and ranks among the top generic manufacturers in the US and emerging global markets.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Godrej Properties Limited recently announced its unaudited financial results for the quarter and nine months ended December 31, 2024.

On February 5, 2025, Godrej Properties share price opened at ₹2,451.00, up from its previous close of ₹2,389.85. At 9:31 AM, the share price of Godrej Properties was trading at ₹2,428.10, up by 1.60% on the NSE.

Sales Highlights

In 9M FY25, the company achieved its highest-ever booking value of ₹19,281 crore, a 48% year-on-year (Y-o-Y) growth, from the sale of 18.21 million sq. ft. of area, reflecting a 54% volume growth. This marks the highest 9-month booking value and area sold by Godrej Properties and any Indian real estate developer to date.

For Q3 FY25, booking value stood at ₹5,446 crore from the sale of 4.07 million sq. ft., a 5% decline Y-o-Y but a 5% growth quarter-on-quarter. This was the sixth consecutive quarter with booking values exceeding ₹5,000 crore. The company has already achieved 71% of its annual guidance for booking value in FY25.

Notably, the Mumbai Metropolitan Region (MMR) recorded a booking value of ₹5,155 crore, a 104% Y-o-Y growth, while Bengaluru reported ₹4,807 crore, a 145% YoY growth during 9M FY25. Godrej Properties launched seven new projects and phases across four cities during the quarter.

Business Development

The company added 4 new projects in Q3 FY25 with an estimated saleable area of 5.9 million sq. ft. and an expected booking value of ₹10,800 crore. In 9M FY25, 12 new projects were added, covering a total saleable area of approximately 16.9 million sq. ft. with an estimated booking value potential of ₹23,450 crore, surpassing the full-year guidance of ₹20,000 crore.

Financial Performance

In Q3 FY25, total income surged by 133% to ₹1,222 crore, EBITDA grew by 85% to ₹280 crore, and net profit increased by 161% to ₹163 crore compared to Q3 FY24.

For 9M FY25, total income grew by 74% to ₹4,203 crore, EBITDA rose by 144% to ₹1,336 crore, and net profit jumped 301% to ₹1,018 crore compared to the same period last year.

Commenting on the performance of Q3 FY2025, the Executive Chairperson of Godrej Properties Limited, Mr Pirojsha Godrej, said, “Godrej Properties delivered a record-breaking calendar year 2024 with its highest ever bookings, collections, operating cashflows, earnings and deliveries. The third quarter of financial year 2025 was the 6th consecutive quarter of more than INR 5,000 crores in bookings underlying the sectoral tailwinds for the residential real estate sector in India.”

He further added, “With a robust launch pipeline, strong balance sheet, and resilient demand, we are on track to surpass our bookings guidance of INR 27,000 cores in FY25 while also achieving our highest-ever cash collections, deliveries, earnings and operating cash flow. We remain focused on building scale through continued market share gains and margin expansion.”

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Dr Agarwals Healthcare IPO opened for subscription on January 29, 2025, and closed on January 31, 2025.

It was a book-built issue of ₹3,027.26 crore. The issue was a combination of a fresh issue of 0.75 crore shares and an offer for sale of 6.78 crore shares. The Dr Agarwals Healthcare IPO price band was set at ₹382 to ₹402 per share.

On Day 3 of subscription, January 31, as of 5:04 PM, Dr Agarwals Healthcare IPO was subscribed 1.49 times. QIBs subscribed 4.41x, NIIs subscribed 0.39x, and retail investors subscribed 0.42x.

The share allotment was finalised on Monday, February 3, 2025, and the shares were listed on BSE and NSE on Tuesday, February 4, 2025.

Dr Agarwals Healthcare Share Price

On the listing day, on the NSE, Dr Agarwals Healthcare share price (NSE: AGARWALEYE) opened at ₹402.00, the same as its issue price of ₹402.00. The share price closed at ₹400.00, down by 0.50%. The stock touched its day’s high at ₹412.90 and day’s low at ₹370.20. The company’s market cap was ₹12,635.19 crore.

On the BSE, Dr Agarwals Healthcare share price closed at ₹401.55, up by 1.17%. The opening price was ₹396.90.

About Dr. Agarwal’s Health Care Limited

Dr Agarwals provides a comprehensive range of eye care services, such as cataract, refractive, and other surgeries. The company also provides consultations, diagnoses, non-surgical treatments, optical products, contact lenses, accessories, and eye care-related pharmaceutical products.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

On Wednesday, February 5, 2025, the Indian benchmark indices Sensex and Nifty 50 are expected to open higher, following gains in global markets. Check out a few stocks that might be in focus during the trading session.

• Tata Power

Tata Power‘s Q3 consolidated net profit surged to ₹1,030 crore, up from ₹953 crore year-on-year (Y-o-Y). Revenue climbed to ₹15,400 crore, compared to ₹14,651 crore. EBITDA jumped to ₹3,352 crore, rising from ₹2,417 crore, while the EBITDA margin improved significantly to 21.78% from 16.50%.

• Lemon Tree Hotels

Lemon Tree Hotels reported a sharp rise in Q3 consolidated net profit, which increased to ₹62.5 crore from ₹35.4 crore Y-o-Y and ₹29.6 crore sequentially. Revenue climbed to ₹360 crore, up from ₹289 crore Y-o-Y. EBITDA rose to ₹184 crore from ₹142 crore, with the EBITDA margin expanding to 51.86% from 48.80%.

• Metropolis Healthcare

Metropolis Healthcare‘s Q3 consolidated net profit improved to ₹31.4 crore, compared to ₹27.15 crore in the previous year. Revenue increased to ₹323 crore, up from ₹290 crore. EBITDA stood at ₹72 crore, higher than ₹64.8 crore, while the EBITDA margin remained stable at 22.31%, marginally up from 22.28%.

• Sun Pharma

Sun Pharma announced that Philogen has completed patient enrollment for the Phase III Fibrosarc trial in soft tissue sarcoma.

• Whirlpool of India

Whirlpool of India‘s Q3 consolidated net profit jumped to ₹44 crore, compared to ₹28 crore Y-o-Y. Revenue expanded to ₹1,700 crore, rising from ₹1,526 crore. EBITDA grew to ₹69.3 crore, up from ₹62.7 crore, while the EBITDA margin stood at 4.06%, slightly lower than 4.08%.

• Indian Energy Exchange (IEX)

Indian Energy Exchange (IEX) recorded a traded volume of 10,910 MU in January, marking a 16% increase Y-o-Y. The average DAM price was ₹4.43/unit, reflecting a 24% decline from the previous year.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

The packaging sector is currently the 5th largest in the Indian economy, playing a key role in driving industrial growth and innovation. A key component of this growth is the paper industry, which boasts a strong structural foundation, with over 900 paper units and an installed capacity nearing 4,990 thousand tons. India also houses 861 paper mills, with 526 units actively operating. In this article, check the best paper stocks in India in February 2025 based on 5yr CAGR and other parameters like market cap and net profit margin.

Best Paper Stocks in February 2025 – Based on 5Y CAGR

Note: The paper stocks list mentioned above is selected from the Paper Products Sector with a market capitalisation of over ₹1,500 crore and sorted based on 5yr CAGR. The details are as of February 3, 2025.

Overview of the Best Paper Stocks in February 2025

1. JK Paper Ltd

JK Paper is a popular player in office papers, coated papers, and packaging boards. For the 9M ended December 31, 2024, the company’s total income was ₹5,111.78 crore, compared to ₹5,110.33 crore during the same period in FY 2024. The company’s profit was ₹334.93 crore, compared to ₹854.50 crore in 9M ended December 31, 2023.

Key metrics:

• ROCE: 19.52%
• ROE: 23.67%

2. West Coast Paper Mills Ltd

West Coast Paper Mills Ltd is one of the oldest producers of paper for printing, writing, and packaging in India. In H1 FY 2025, the company’s revenue dropped 13% to ₹2,101 crore, compared to ₹2,403 crore in H1 FY 2024. In H1 FY 2025, the company’s profit was ₹222 crore, compared to ₹497 crore in H1 FY 2024, a drop of 55%.

Key metrics:

• ROCE: 25.30%
• ROE: 20.13%

3. Seshasayee Paper and Boards Ltd

Seshasayee Paper and Boards Ltd is engaged in the business of manufacturing and selling printing and writing paper. For the 9M ended December 31, 2024, the company’s total income was ₹1,302.44 crore, compared to ₹1,299.09 crore during the same period in FY 2024. The company’s profit was ₹82.10 crore, compared to ₹213.93 crore in 9M ended December 31, 2023.

Key metrics:

• ROCE: 17.28%
• ROE: 15.27%

4. Andhra Paper Ltd

Andhra Paper is engaged in the business of manufacturing and sale of paper, pulp and paper and paper board. In H1 FY 2025, the company’s revenue dropped 20% to ₹804 crore, compared to ₹1,003 crore in H1 FY 2024. In H1 FY 2025, the company’s profit was ₹69 crore, with a drop of 68% from ₹219 crore in H1 FY 2024.

Key metrics:

• ROCE: 22.64%
• ROE: 19.55%

Best Paper Stocks in February 2025 – Based on Market Cap

Note: The paper stocks list mentioned above is selected from the Paper Products Sector with a market capitalisation of over ₹1,000 crore and sorted based on market cap. The details are as of February 3, 2025.

Best Paper Stocks in February 2025 – Based on Net Profit Margin

Note: The paper stocks list mentioned above is selected from the Paper Products Sector with a market capitalisation of over ₹1,000 crore and sorted based on net profit margin. The details are as of February 3, 2025.

Pros of Investing in Paper Stocks

• Growing Demand: Increasing demand for sustainable packaging, driven by global environmental consciousness, can boost the paper industry.
• Diverse Applications: Paper is used across industries like packaging, education, FMCG, and e-commerce, ensuring steady demand.
• Government Support: Policies encouraging eco-friendly practices and bans on single-use plastics create opportunities for paper manufacturers.
• Recyclability Focus: Companies adopting recycled paper production align with ESG (Environmental, Social, and Governance) standards, attracting sustainable investors.

Risks of Investing in Paper Stocks

• Raw Material Volatility: Prices of key raw materials like wood pulp and wastepaper can fluctuate, impacting profitability.
• Environmental Regulations: Stringent policies related to emissions and resource consumption may increase compliance costs.
• High Competition: The sector faces competition from global players and alternatives like digital solutions.

Conclusion

Apart from the stocks listed above, there are several other paper sector stocks in India. Before investing in any company, know the company’s business, financial performance and future prospects.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Anant Raj Limited has been in focus on Monday post the announcement of the financial results for the quarter-ended December 31, 2024.

On February 3, 2025, Anant Raj share price (NSE: ANANTRAJ) opened at ₹635.00, down from its previous close of ₹638.40. At 10:54 AM, the share price of Anant Raj was trading at ₹595.95, down by 6.65% on the NSE. The stock price touched its 52-week high recently at ₹947.90 on January 8, 2025.

Q3 FY 2025 Financial Highlights

For the quarter ending December 31, 2024, the company reported a total income of ₹543.97 crore, up from ₹523.75 crore in the previous quarter (September 30, 2024) and ₹401.02 crore in the same quarter last year (December 31, 2023).

Profit for the period for Q3 FY25 stood at ₹110.37 crore, showing an increase from ₹105.65 crore in Q2 FY25 and ₹71.43 crore in Q3 FY24.

9M Ending December 31, 2024 Financial Highlights

For the nine-month period ending December 31, 2024, the company posted a profit of ₹307.03 crore, compared to ₹181.92 crore in the same period of the previous year. The total income for the first nine months of FY25 was ₹1,549.38 crore, up from ₹1,067.62 crore during the same period in FY24.

About Anant Raj Ltd

Anant Raj Ltd, founded in 1985 by Ashok Sarin as Anant Raj Clay Products, specializes in the development and construction of IT parks, hospitality projects, SEZs, office complexes, shopping malls, and residential properties across Delhi, Haryana, Andhra Pradesh, Rajasthan, and the NCR region. The company has completed over 20 million square feet of real estate projects, spanning various sectors such as housing, commercial, IT parks, shopping malls, hospitality, residential, and affordable housing.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Jupiter Wagons Ltd has been in focus on Monday. On February 3, 2025, Jupiter Wagons share price opened at ₹370.00, up from its previous close of ₹377.65. At 11:18 AM, the share price of Jupiter Wagons was trading at ₹353.35, down by 6.43% on the NSE.

Railway Budget Allocation Unchanged for 2025

In the Budget documents released on Saturday, it was revealed that the allocation for the railways sector remains unchanged at ₹2.55 lakh crore for the financial year 2026. This figure mirrors the allocation for the financial year 2025.

Railways Minister Ashwini Vaishnaw further stated that the allocation for safety would increase to ₹1.16 lakh crore, and the sector is projected to handle over 1.6 billion tonnes of cargo by FY 2026. With ₹4.16 lakh crore worth of projects in the pipeline, the railway sector continues to be a focal point for growth and development.

Q3 FY25 Performance Highlights

Jupiter Wagons Ltd’s Q3 FY25 revenue from operations stood at ₹1,029.8 crore, reflecting a 15% year-on-year increase. EBITDA for the quarter was ₹148.7 crore, marking a 19.5% growth. The company’s PAT for Q3 FY25 was ₹96.4 crore, up by 18.4% year-on-year, with a healthy PAT margin of 9.2%.

9MFY25 Performance & Robust Order Book

For the nine months ending December 31, 2024, Jupiter Wagons posted a revenue of ₹2,918.7 crore, showing a 15.4% increase year-on-year. EBITDA for the period reached ₹424.8 crore, a 24.3% growth, while PAT stood at ₹277.7 crore, up by 22.7%. The company’s order book was totalling ₹6,320 crore as of December 2024.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.